Special Issue

Neuropsychiatric and Quality of Life (QoL) Aspects of Multiple Sclerosis

Message from the Guest Editor

Multiple sclerosis (MS) is a common chronic neurologic condition affecting young adults. MS can present with a variety of sensorimotor as well as neuropsychiatric symptoms and affects quality of life a lot. Thus, neuropsychiatric comorbidity secondary to MS is becoming an important issue in the MS medical care, and therapeutic efforts strongly depend on these dimensions. Moreover, the chronic aspect of the disease, the individual sociodemographic situations and the individual premorbid characteristics, together with the brain impairment itself influence neuropsychiatric symptoms in MS and interact one with another. In addition, other disease-related medical factors such as the MS therapy itself, and biographical factors such as environmental, social and personality factors may influence the ability to cope with and react to such neuropsychiatric symptoms. This Special Issue covers the broad range of research aimed to elucidate the interrelation between cognitive and neuropsychiatric conditions and their impact on mental health and quality of life in multiple sclerosis. Original high-quality papers and reviews including single-case studies are welcome.

Guest Editor

Prof. Dr. Pasquale Calabrese

Neuropsychology and Behavioral Neurology Unit, Division of Molecular and Cognitive Neuroscience, Department of Psychology, University of Basel, Birmannsgasse 8, 4055 Basel, Switzerland

Deadline for manuscript submissions

closed (31 August 2024)



Sclerosis

an Open Access Journal by MDPI



mdpi.com/si/189168

Sclerosis
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
sclerosis@mdpi.com

mdpi.com/journal/ sclerosis





Sclerosis

an Open Access Journal by MDPI



About the Journal

Message from the Editor-in-Chief

Welcome to Sclerosis.

Sclerosis is a term that encompasses various conditions that involve the stiffening and scarring of tissues and organs. It is a pathologic process of some highly prevalent diseases, such as multiple sclerosis, glomerulosclerosis, atherosclerosis, and more rare diseases, such as amyotrophic lateral sclerosis, systemic sclerosis, and tuberous sclerosis.

Sclerosis aims to provide a platform for dissemination of cutting-edge research and clinical practice in the field. Looking to similarities and differences among "sclerotic" diseases, we aim at identifying shared pathological mechanisms and risk factors, management pathways, and drugs with repurposing potential, while also exploring preventive and therapeutic strategies.

Editor-in-Chief

Dr. Maurizio A. Leone

- Scientific Direction, Casa Sollievo della Sofferenza, 71013 San Giovanni Rotondo, Italy
- 2. Istituto di Ricerche Farmacologiche "Mario Negri", 20156 Milano, Italy

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

first decisions in 16 days; acceptance to publication in 5.8 days (median values for MDPI journals in the first half of 2024).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.

